title: Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
abstract: A major challenge with pancreatic cancer management is in the discrimination of clearly resectable tumors from those that would likely be accompanied by a positive resection margin if upfront surgery was attempted. The standard of care for clearly resectable pancreatic cancer remains surgery followed by adjuvant therapy, but there is considerable controversy over whether such therapeutic adjuvant strategies should include radiotherapy. Furthermore, in a malignancy with such high rates of distant metastasis, investigators are now exploring the feasibility and outcomes of delivering therapy in the neoadjuvant setting, both for clearly resectable as well as borderline resectable tumors. In this review, we explore the current standard of care of upfront surgery for clearly resectable cancers followed by adjuvant therapy, focusing on the role of radiotherapy. We highlight the difficulties in interpreting a literature fraught with inconsistencies in how resectable vs borderline resectable cancers are defined and treated. Finally, we explore the role of neoadjuvant strategies in the modern era.
authors.affiliation: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: Sarah.hoffe@moffitt.org.
authors.forename: Sarah
authors.initials: S
authors.lastname: Hoffe
authors.affiliation: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL.
authors.forename: Nikhil
authors.initials: N
authors.lastname: Rao
authors.affiliation: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL.
authors.forename: Ravi
authors.initials: R
authors.lastname: Shridhar
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018714:Radiotherapy, Adjuvant / Q000379:methods; D016896:Treatment Outcome